Neurology Scandal Patients ‘Must Get Access To The Truth’ – 4ni.co.uk

Patients misdiagnosed in the Neurology scandal must get access to the truth about what happened to them, Sinn Fin MLA Carl N Chuiln has said.

Speaking after the Belfast Trust appeared before the Neurology APG, the North Belfast MLA said: "It is unacceptable that patients and families impacted by the neurology scandal are still waiting for truth and accountability.

"The Independent Inquiry report is nothing short of damming and has cataloged missed opportunities to address their treatment.

"The RQIA report on governance in outpatients - published in Feb 2020 - made 26 recommendations for improvements in Neurology services, and for many families, they feel that very little progress has been made since then.

"Former patients have had their confidence rocked and the Belfast Trust need to do more to support all those failed by Michael Watt.

"Sinn Fin will continue to support the victims and their families in their campaign for truth and accountability."

Continue reading here:
Neurology Scandal Patients 'Must Get Access To The Truth' - 4ni.co.uk

Hartford Healthcare neurologist excited about possible new Alzheimers disease treatment – WTNH.com

HARTFORD, Conn. (WTNH) A Hartford Healthcare neurologist is cautiously excited about a new treatments ability to prevent memory loss in patients with Alzheimers disease.

Dr. Amy Sanders has been watching research indicating that the drug lecanemab can either slow or altogether stop cognitive decline.

The results, she said, werent surprising.

That has been the Holy Grail of Alzheimers disease pharmaceutical research for decades, so this is the first time my heart went pitty pat, when I read these announcements, Sanders said.

Lecanemab clears amyloid plaques, which are protein deposits linked to dementia.

Weve had agents that could clear amyloid plaques in the past, but we have not had the one-two punch, Sanders said. And its possible that we now have it.

The 1,800 people in the clinical trial had either a mild form of Alzheimers disease, or a pre-Alzheimers condition that is considered to be a mild cognitive impairment.

While the data wont be released until the end of November, the Alzheimers Association has called the study a major development, and said that more drugs are in the pipeline.

See the rest here:
Hartford Healthcare neurologist excited about possible new Alzheimers disease treatment - WTNH.com

DWP: You could be entitled to 156 per week if you have any of these 70 neurological conditions – Cambridgeshire Live

The Department of Work and Pensions offers extra support to people with a range of neurological conditions. Illnesses such as epilepsy, motor neurone disease and multiple sclerosis are all covered by the Personal Independent Payment (PIP).

According to the DWP nearly 3 million people in the UK are claiming extra support and over 300,000 claim it for a neurological condition. The PIP benefit is available to over 70 conditions and can help families struggling under the cost of living crisis, The Daily Record reports.

You could be entitled to 156 per week if you have any of these 70 neurological conditions. The PIP can be claimed as long as the following applies:

Read more: DWP: Benefits may not rise with the rate of inflation warns treasury

Cerebrovascular disease

Epilepsy

Non epileptic disturbance of consciousness

Movement disorders

Multiple sclerosis

Benign tumours

Hydrocephalus

Headache

Head injury

Spinal cord compression

Degenerative neuronal diseases

Cerebral palsy

Spina bifida

Ataxia

Neuropathy

Peripheral nerve injury

Disease of muscle

Muscular dystrophy

READ NEXT:

DWP warns pensioners claiming Attendance Allowance could risk going to court

DWP issues urgent warning over cost of living scammers who offer fake energy bill discounts

Argos' 25 electric blanket costing pennies to run sells out across Cambridgeshire: alternatives and where it's still available

DWP announces millions could receive an extra 600 with Winter Fuel Payment

Read more:
DWP: You could be entitled to 156 per week if you have any of these 70 neurological conditions - Cambridgeshire Live

Gene Therapy on Neurological Diseases Market Size, Share, Segmentation, And Forecast 2030 – PharmiWeb.com

Pune, Maharashtra, September 29 2022 (Wiredrelease) Market.Biz :Discover the game-changing elements and trends that are impacting Gene Therapy in Neurological Diseases Market With Market.biz, you can navigate the complexities of Gene Therapy in the Neurological Diseases industry.

Global Gene Therapy on Neurological Diseases Market Analysis:

The Gene Therapy on Neurological Diseases reports overview is a compilation of the most recent trends and figures that reveal a broad analysis of the market drivers, revenue share, segmentation, and geographical markets. It investigates a wide range of topics, including regional market scope, product-market various applications, market size according to a specific product, sales and revenue by region, production cost analysis, supply chain, market influencing factors analysis, market size estimates, and more. This market analysis includes an overview of Gene Therapy in the Neurological Diseases industry, a look at the target market, a competition analysis, business projections, and regulations. The following are the main points discussed:

Description and forecast for the industry:

First and foremost, this is where youll discover information about the present situation of the Gene Therapy in Neurological Diseases business and where its heading. This section includes industry indicators such as size, trends, life cycle, and predicted growth. This report includes statistics to back up your company concept. The worldwide Gene Therapy on Neurological Diseases market is divided into North America; Europe; Asia Pacific; Latin America; The Middle East & Africa.

Request a PDF Sample: https://market.biz/report/global-gene-therapy-on-neurological-diseases-market-gm/#requestforsample

Market Segmentation Analysis

This studys target market segment contains the following:

Demographics such as age, income, and geography are included in the user persona and attributes. It informs you of their hobbies and purchasing habits, as well as the greatest position to suit their demands.

Market size: What is the potential size of the Gene Therapy on Neurological Diseases market for your company? It reveals the consumption in the Gene Therapy on Neurological Diseases business according on Type and application. With respect to Type, segmentation is carried out under Viral Gene Therapy; Non-viral Gene Therapy. And concerning the applications, segmentation Hospital; Clinic

Analysis of competitors: Learn about Gene Therapy on Neurological Diseases competitors. The study not only informs you about your competition, but it also identifies their flaws. Is there a client base that is underserved? What do you have to offer that other companies dont? The competitive analysis includes the following elements:

Direct competitors include: What other businesses provide comparable goods and services? Which firms are your genuine rivals? All of these issues are addressed in the paper. This section also provides Biogen; Novartis; Sarepta Therapeutics analysis.

Indirect competitors: Similarly, this report informs you that you are not competing with Gene Therapy on Neurological Diseases firms, but rather report Cat companies.

What are the strengths and shortcomings of your competition? Where are they falling short? Learn how to discover opportunities to flourish when others are failing.

What are the possible drawbacks of joining the Gene Therapy on Neurological Diseases market? What is the entrance fee? Is it unreasonably expensive or simple to enter? This is where you look at your flaws.

The opportunity window: Finally, do you plan to enter the Gene Therapy on Neurological Diseases sector using time-sensitive technology? Is it necessary to enter early to capitalise on an emerging market? As a result, the study addresses all of these concerns.

So, what will the reality be in 2023? Inquire, learn, and get https://market.biz/report/global-gene-therapy-on-neurological-diseases-market-gm/#inquiry

Projections: Similarly, We provided deliberate forecasting rather than hockey-stick forecasting. Market share We have also provided consumer consumption behaviour. Only you will comprehend how much of the Gene Therapy on Neurological Diseases sector you have a chance to capture once you know how much your prospective clients can pay. And this is where we came up with actual statistics and data. Bottom-up predictions will show how your marketing and sales activities will allow you to capture a specific share of the market.

Pricing and gross margin: We also design a pricing structure. The difference between your Gene Therapy on Neurological Diseases expenditures and the Gene Therapy on Neurological Diseases sales price is your gross margin. These positive estimates might not only serve as a guide, but also as an incentive.

Regulations: Is there any special governmental rules or limits on the Global Gene Therapy on Neurological Diseases Market? If thats the case, it brought them up here and spoke about how to comply with them.

Success Factors: Above all, what criteria distinguish success from failure? We identified key parameters based on Gene Therapy on Neurological Diseases categories, which include pricing, value, availability, features, financing, upgrades or return policies, and customer service.

Most importantly, this market study can assist you in identifying market blind spots.

Buy Report: https://market.biz/checkout/?reportId=839259&type=Single%20User

Thank you for reading it all the way to this point.

Contact number: +1 (857)4450045, +91 9130855334.Email: inquiry@market.biz

Immunity Booster Supplement Market Will Help To Minimize The Risk Of Virus Infection: https://www.pharmiweb.com/press-release/2022-09-26/immunity-booster-supplement-market-will-help-to-minimize-the-risk-of-virus-infection

High-end Fish Oil Market Leading Industries, and Upcoming Opportunity Analysis To 2030: https://www.pharmiweb.com/press-release/2022-09-28/high-end-fish-oil-market-leading-industries-and-upcoming-opportunity-analysis-to-2030

Therapeutic Proteins for Cardiovascular Disorders Treatment Market Leading Vendors, And Forecast Assessment To 2030: https://www.pharmiweb.com/press-release/2022-09-28/therapeutic-proteins-for-cardiovascular-disorders-treatment-market-leading-vendors-and-forecast-ass

Veterinary Infectious Diseases Therapeutics Market Will Grow With Highest CAGR During Forecast Period Till 2030: https://www.pharmiweb.com/press-release/2022-09-28/veterinary-infectious-diseases-therapeutics-market-will-grow-with-highest-cagr-during-forecast-perio

This content has been published by Market.Biz company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Originally posted here:
Gene Therapy on Neurological Diseases Market Size, Share, Segmentation, And Forecast 2030 - PharmiWeb.com

Precision Surgery Device Market Size to Hit USD 18.99 Billion by 2030 | Rising Demand in Neurological Surgical Procedures & High Investment by Top…

The Brainy Insights

Global precision surgery device market growth would be driven by the increasing incidence of accidents, sports injuries, and other diseases that require surgical intervention. The growing research and development of innovative wound closure devices are gaining traction in the medical industry. The North American region emerged as the largest market for the global precision surgery device market, with a 37.66% share of the market revenue in 2021.

Newark, Sept. 30, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the globalprecision surgery device market is expected to grow from USD 5.14 billion in 2021 to USD 18.99 billion by 2030, at a CAGR of 15.63% during the forecast period 2022-2030.

A sedentary lifestyle, lack of exercise, bad eating habits, and a rise in the number of hours spent in front of laptops and smartphone displays have all contributed to an increase in the number of people with acute and chronic diseases. Cardiovascular, respiratory, and orthopedic diseases are becoming more common among the aging population. Precision surgery devices are increasingly used in surgical procedures due to their minimally invasive nature and quicker healing times. The global market is driven during the forecast period by the rising usage of precision surgery equipment and the rising prevalence of disorders.

Request PDF Brochure: https://www.thebrainyinsights.com/enquiry/sample-request/12935

Accidents are also among the leading causes of death worldwide, which will drive the market's growth. Major players have invested capital into research and system development to meet the growing need for precision surgery technologies. Robust technological advancements and developments in precision surgery equipment will boost industry efficiency and competitiveness, fostering the sector's expansion and creating profitable prospects for market participants. However, the high cost of precision surgery devices can hamper the market's growth. Stringent government guidelines and regulations will also challenge the market forecast period. The lack of skilled professionals to operate these devices will also limit the market's growth. Innovations and comprehensive approval mechanisms can help overcome these challenges and provide an impetus to the global precision surgery device market.

Story continues

Competitive Strategy

To enhance their market position in the global precision surgery device market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships.

In August 2022, Edwards Lifesciences' Pascal Precision system, its newest treatment for mitral and tricuspid regurgitation patients, received a CE mark. With the regulatory nod, Edwards will be able to launch the surgical device in the European market. According to a statement offered by the company's CEO, the firm is scheduled to receive approval from the FDA before year-end.

Market Growth & Trends

The rise in accidents, sports injuries, and other conditions requiring surgical intervention will fuel the market for precision surgery devices. The medical sector is witnessing an increase in the study, research, and development of novel wound closure devices, which is anticipated to drive product innovations in the market. Precision surgery devices are becoming more widely used in healthcare due to their minimally invasive design and improved post-operative healing. Precision surgery gadgets are less painful than open operations, so the aging population will drive the market for them. Additionally, it lessens discomfort and enables the patient to reduce scarring. The dangers of open surgery, such as harm to internal organs, are minimized. Medical experts can also use precision surgery tools to repair the little anomalies that were previously impossible to fix. Advances in artificial intelligence and machine learning are creating lucrative opportunities in the market. Precision surgery equipment is becoming more widely used due to the use of robotics and the internet of things (IoT) in medicine to increase hospital success or survival rates.

If you have any questions, please feel free to contact our analyst at: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/12935

Key Findings

In 2021, the cardiovascular segment dominated the market with the largest market share of 45% and market revenue of 2.31 billion.

The application segment is divided into orthopedic, neurosurgery, cardiovascular, wound closure, and others. In 2021, the cardiovascular segment dominated the market with the largest market share of 45% and market revenue of 2.31 billion.

The handheld surgical devices segment is expected to grow at the fastest CAGR of 17.15% over the forecast period.

The type segment is divided into handheld surgical devices, electrosurgical devices, and others. Over the forecast period, the handheld surgical devices segment is expected to grow at the fastest CAGR of 17.15%.

In 2021, the hospitals' segment accounted for the largest share of the market, with 53% and a market revenue of 2.72 billion.

The end-user segment is divided into hospitals, specialty clinics, ambulatory settings, long-term care centers, and others. In 2021, the hospitals' segment accounted for the largest share of the market, with 53% and a market revenue of 2.72 billion.

Regional Segment Analysis of the Precision Surgery Device Market

North America (U.S., Canada, Mexico) Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and the Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, the North American region emerged as the largest market for the global precision surgery device market, with a market share of around 37.66% and 1.93 billion of the market revenue in 2021. Healthcare is more readily available and more reasonably priced for the populace due to the high per capita income and the established insurance market with favorable reimbursement policies in the region. The growing elderly population also fuels the growing need for surgery. The market for precision surgery devices has benefited from the growing need for reconstructive, plastic, and other procedures to enhance body aesthetics. Furthermore, the rising government spending on healthcare infrastructure will influence the market's growth in the upcoming years.

Interested in Procuring This Report? Visit Here: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/12935

Key players operating in the global precision surgery device market are:

Alcon Aspen Surgical B. Braun SE Baxter Boston Scientific Johnson & Johnson Medtronic PLC Siemens Healthcare GmbH Stryker Corporation Zimmer Biomet

This study forecasts global, regional, and country revenue from 2019 to 2030. The Brainy Insights has segmented the global precision surgery device market based on the below-mentioned segments:

Global Precision Surgery Device Market by Application:

Orthopedic Neurosurgery Cardiovascular Wound Closure Others

Global Precision Surgery Device Market by Type:

Handheld Surgical Devices Electrosurgical Devices Others

Global Precision Surgery Device Market by End User:

Hospitals Specialty Clinics Ambulatory Settings Long-Term Care Centers Others

About the report:

The global precision surgery device market is analyzed based on value (USD Billion). All the segments have been analyzed on a worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash DHead of Business DevelopmentPhone: +1-315-215-1633Email: sales@thebrainyinsights.comWeb: http://www.thebrainyinsights.com

Here is the original post:
Precision Surgery Device Market Size to Hit USD 18.99 Billion by 2030 | Rising Demand in Neurological Surgical Procedures & High Investment by Top...

Engineering the Perfect Baby | MIT Technology Review

Indeed, some people are adamant that germ-line engineering is being pushed ahead with false arguments. That is the view of Edward Lanphier, CEO of Sangamo Biosciences, a California biotechnology company that is using another gene-editing technique, called zinc fingers nucleases, to try to treat HIV in adults by altering their blood cells. Weve looked at [germ-line engineering] for a disease rationale, and there is none, he says. You can do it. But there really isnt a medical reason. People say, well, we dont want children born with this, or born with thatbut its a completely false argument and a slippery slope toward much more unacceptable uses.

Critics cite a host of fears. Children would be the subject of experiments. Parents would be influenced by genetic advertising from IVF clinics. Germ-line engineering would encourage the spread of allegedly superior traits. And it would affect people not yet born, without their being able to agree to it. The American Medical Association, for instance, holds that germ-line engineering shouldnt be done at this time because it affects the welfare of future generations and could cause unpredictable and irreversible results. But like a lot of official statements that forbid changing the genome, the AMAs, which was last updated in 1996, predates todays technology. A lot of people just agreed to these statements, says Greely. It wasnt hard to renounce something that you couldnt do.

The fear? A dystopia of superpeople and designer babies for those who can afford it.

Others predict that hard-to-oppose medical uses will be identified. A couple with several genetic diseases at once might not be able to find a suitable embryo. Treating infertility is another possibility. Some men dont produce any sperm, a condition called azoospermia. One cause is a genetic defect in which a region of about one million to six million DNA letters is missing from the Y chromosome. It might be possible to take a skin cell from such a man, turn it into a stem cell, repair the DNA, and then make sperm, says Werner Neuhausser, a young Austrian doctor who splits his time between the Boston IVF fertility-clinic network and Harvards Stem Cell Institute. That will change medicine forever, right? You could cure infertility, that is for sure, he says.

I spoke with Church several times by telephone over the last few months, and he told me whats driving everything is the incredible specificity of CRISPR. Although not all the details have been worked out, he thinks the technology could replace DNA letters essentially without side effects. He says this is what makes it tempting to use. Church says his laboratory is focused mostly on experiments in engineering animals. He added that his lab would not make or edit human embryos, calling such a step not our style.

What is Churchs style is human enhancement. And hes been making a broad case that CRISPR can do more than eliminate disease genes. It can lead to augmentation. At meetings, some involving groups of transhumanists interested in next steps for human evolution, Church likes to show a slide on which he lists naturally occurring variants of around 10 genes that, when people are born with them, confer extraordinary qualities or resistance to disease. One makes your bones so hard theyll break a surgical drill. Another drastically cuts the risk of heart attacks. And a variant of the gene for the amyloid precursor protein, or APP, was found by Icelandic researchers to protect against Alzheimers. People with it never get dementia and remain sharp into old age.

Church thinks CRISPR could be used to provide people with favorable versions of genes, making DNA edits that would act as vaccines against some of the most common diseases we face today. Although he told me anything edgy should be done only to adults who can consent, its obvious to him that the earlier such interventions occur, the better.

Church tends to dodge questions about genetically modified babies. The idea of improving the human species has always had enormously bad press, he wrote in the introduction to Regenesis, his 2012 book on synthetic biology, whose cover was a painting by Eustache Le Sueur of a bearded God creating the world. But thats ultimately what hes suggesting: enhancements in the form of protective genes. An argument will be made that the ultimate prevention is that the earlier you go, the better the prevention, he told an audience at MITs Media Lab last spring. I do think its the ultimate preventive, if we get to the point where its very inexpensive, extremely safe, and very predictable. Church, who has a less cautious side, proceeded to tell the audience that he thought changing genes is going to get to the point where its like you are doing the equivalent of cosmetic surgery.

Some thinkers have concluded that we should not pass up the chance to make improvements to our species. The human genome is not perfect, says John Harris, a bioethicist at Manchester University, in the U.K. Its ethically imperative to positively support this technology. By some measures, U.S. public opinion is not particularly negative toward the idea. A Pew Research survey carried out last August found that 46 percent of adults approved of genetic modification of babies to reduce the risk of serious diseases.

Link:
Engineering the Perfect Baby | MIT Technology Review

CIA Just Invested In Woolly Mammoth Resurrection Tech – The Intercept

As a rapidly advancing climate emergency turns the planet ever hotter, the Dallas-based biotechnology company Colossal Biosciences has a vision: To see the Woolly Mammoth thunder upon the tundra once again. Founders George Church and Ben Lamm have already racked up an impressive list of high-profile funders and investors, including Peter Thiel, Tony Robbins, Paris Hilton, Winklevoss Capital and, according to the public portfolio its venture capital arm released this month, the CIA.

Colossal says it hopes to use advanced genetic sequencing to resurrect two extinct mammals not just the giant, ice age mammoth, but also a mid-sized marsupial known as the thylacine, or Tasmanian tiger, that died out less than a century ago. On its website, the company vows: Combining the science of genetics with the business of discovery, we endeavor to jumpstart natures ancestral heartbeat.

In-Q-Tel, its new investor, is registered as a nonprofit venture capital firm funded by the CIA. On its surface, the group funds technology startups with the potential to safeguard national security. In addition to its long-standing pursuit of intelligence and weapons technologies, the CIA outfit has lately displayed an increased interest in biotechnology and particularly DNA sequencing.

Why the interest in a company like Colossal, which was founded with a mission to de-extinct the wooly mammoth and other species? reads an In-Q-Tel blog post published on September 22. Strategically, its less about the mammoths and more about the capability.

Biotechnology and the broader bioeconomy are critical for humanity to further develop. It is important for all facets of our government to develop them and have an understanding of what is possible, Colossal co-founder Ben Lammwrote in an email to The Intercept. (A spokesperson for Lamm stressed that while Thiel provided Church with$100,000 in funding to launchthe woolly mammoth project that became Colossal, he is not a stakeholderlike Robbins, Hilton, Winklevoss Capital, and In-Q-Tel.)

Colossal uses CRISPR gene editing, a method of genetic engineering based on a naturally occurring type of DNA sequence. CRISPR sequences present on their own in some bacterial cells and act as an immune defense system, allowing the cellto detect and excise viral material thattries to invade. The eponymous gene editing technique was developed to function the same way, allowing users to snip unwanted genes and program a more ideal version of the genetic code.

CRISPR is the use of genetic scissors, Robert Klitzman, a bioethicist at Columbia University and a prominent voice of caution on genetic engineering, told The Intercept. Youre going into DNA, which is a 3-billion-molecule-long chain, and clipping some of it out and replacing it. You can clip out bad mutations and put in good genes, but these editing scissors can also take out too much.

The embrace of this technology, according to In-Q-Tels blog post, will help allow U.S. government agencies to read, write, and edit genetic material, and, importantly, tosteerglobal biological phenomena that impact nation-to-nation competition whileenabling the United States to help set the ethical, as well as the technological, standards for its use.

In-Q-Tel did not respond to The Intercepts requests for comment.

In recent years, the venture firms portfolio has expanded to include Ginkgo Bioworks, a bioengineering startup focused on manufacturing bacteria for biofuel and other industrial uses; Claremont BioSolutions, a firm that produces DNA sequencing hardware; Biomatrica and T2 Biosystems, two manufacturers for DNA testing components; and Metabiota, an infectious disease mapping and risk analysis database powered by artificial intelligence. As The Intercept reported in 2016, In-Q-Tel also invested in Clearista, a skincare brand that removes a thin outer epidermal layer to reveal a fresher face beneath it and allow DNA collection from the skin cells scraped off.

President Joe Bidens administration signaled its prioritization of related advances earlier this month, when Biden signed an executive order on biotechnology and biomanufacturing. The order includes directives to spur public-private collaboration, bolster biological risk management, expand bioenergy-based products, and engage the international community to enhance biotechnology R&D cooperation in a way that is consistent with United States principles and values.

The governments penchant for controversial biotechnology long predates the Biden administration. In 2001, a New York Times investigation found that American defense agencies under Presidents George W. Bush and Bill Clinton had continued to experiment with biological weapons, despite a 1972 international treaty prohibiting them. In 2011, The Guardian revealed that the CIA under President Barack Obama organized a fake Hepatitis B vaccine drive in Pakistan that sought to locate family members of Osama bin Laden through nonconsensual DNA collection, leading the agency to eventually promise a cessation of falseimmunization campaigns.

CIA Labs, a 2020 initiative overseen by Donald Trumps CIA director, Gina Haspel infamous for running a torture laboratory in Thailand follows a model similar to In-Q-Tels. The program created a research network to incubate top talent and technology for use across U.S. defense agencies, while simultaneously allowing participating CIA officers to personally profit off their research and patents.

In-Q-Tel board members are allowed to sit on the boards of companies in which the firm invests, raising ethics concerns over howthe non-profit selects companies to back with government dollars. A 2016 Wall Street Journal investigation found that almost half of In-Q-Tel board members were connected to the companies where it had invested.

The size of In-Q-Tels stake in Colossal wont be known until the nonprofit releases its financial statements next year, but the investment may provide a boon on reputation alone: In-Q-Tel has claimed that every dollar it invests in a business attracts 15 more from other investors.

Colossals co-founders, Lamm and Church, represent the ventures business and science minds, respectively. Lamm, a self-proclaimed serial technology entrepreneur, founded his first company as a senior in college, then pivoted to mobile apps and artificial intelligence before helping to start Colossal.

Church a Harvard geneticist, genome-based dating app visionary, and former Jeffrey Epstein funding recipient has proposed the revival of extinct species before. Speaking to Der Spiegel in 2013, Church suggested the resurrection of the Neanderthal an idea met with controversy because it would require technology capable of human cloning.

We can clone all kinds of mammals, so its very likely that we could clone a human, Church said. Why shouldnt we be able to do so? When the interviewer reminded him of a ban on human cloning, Church said, And laws can change, by the way.

Even when the methods used for de-extinction are legal, many scientists are skeptical of its promise. In a 2017 paper for Nature Ecology & Evolution, a group of biologists from Canada, Australia, and New Zealand found that [s]pending limited resources on de-extinction could lead to net biodiversity loss.

De-extinction is a fairytale science, Jeremy Austin, a University of Adelaide professor and director of the Australian Center for Ancient DNA,toldthe Sydney Morning Herald over the summer, when Colossal pledged to sink $10 million into the University of Melbourne for its Tasmanian tiger project. Its pretty clear to people like me that thylacine or mammoth de-extinction is more about media attention for the scientists and less about doing serious science.

Critics who say de-extinction of genes to create proxy species is impossible are critics who are simply not fully informed and do not know the science. We have been clear from day one that on the path to de-extinction we will be developing technologies which we hope to be beneficial to both human healthcare as
well as conservation, Lamm wrote to The Intercept. We will conitnue [sic] to share these technologies we develop with the world.

It remains to be seen if Colossal, with In-Q-Tels backing, can make good on its promises. And its unclear what, exactly, the intelligence world might gain from the use of CRISPR. But perhaps the CIA shares the companys altruistic, if vague, motives: To advance the economies of biology and healing through genetics. To make humanity more human. And to reawaken the lost wilds of Earth. So we, and our planet, can breathe easier.

Update: September 28, 2022, 1:00 p.m. ETThis story has been updated with a statement from Colossal co-founder Ben Lamm.

Continue reading here:
CIA Just Invested In Woolly Mammoth Resurrection Tech - The Intercept

‘Vesper’ Ending, Explained: What Happens To Vesper And Camellia? What Does He Do With The Seeds? | DMT – DMT

Vesper is a delightful concoction of detail and simplicity, one that is easy to gulp down and leaves an effect for a long time. Although the drama films premise is a science-fiction post-apocalyptic world, its story is universal and relatable enough to make it seem almost like a coming-of-age tale. With the eponymous protagonist, Vesper, learning to find her way and take responsibilities in a world with no hope, the adventures she comes across and the ultimate choice that she has to make turn Vesper into a lovely tale of hope as well.

Spoilers Ahead

Set in the future world termed the New Dark Ages, the plot unfolds in a barren wasteland. Humans had made an attempt to prevent the ecological crisis by investing in genetic technology largely, but the process ultimately had failed. Instead, genetically engineered viruses and other harmful organisms escaped into the world and killed off vast numbers of life forms. While some humans survived, all food sources, be they plants or animals, were wiped out and left human society starkly divided. On the one hand are the rich and affluent, who live in protected cities called citadels, and on the other hand, everyone else, who are never permitted into these citadels. Although these citadels grow their own food from the seeds they had presumably preserved before the apocalypse, those outside rely only on these seeds that the citadels trade with them in exchange for other items. Even more harshly, these seeds traded are coded to produce a single harvest, and therefore the outsiders need to forever stay in need of the mercy of the citadels.

In such a world, Vesper is a thirteen-year-old girl with an exceptional talent for studying organisms of this new world and creating new life by mixing them with each other. However, her responsibilities weigh more than her respite for passionate experimentation, for Vesper has to look after her ailing father, especially since her mother left them about a year or so ago. The father, Darius, is bedridden and cannot move or speak on his own but communicates through the body of a metallic drone. It is with this drone, essentially her father, that Vesper goes around searching for new plants and forms of life to gather for food, medicine, and her own research. The world has other factions of danger, too, for a group of humans calling themselves the pilgrims mysteriously roam around, scavenging any and every metal they can find, and Vespers mother, too, had joined this group of pilgrims. Along with that, there are also raiders and bandits who go around looting and, on one occasion, visit Vespers house as well, taking away all the power resources. When she finds her father struggling for life without power because his heart and other organs are supported and kept running through external power, Vesper looks for help at her uncle Jonas farm. However, Jonas is a crooked leader of a group of outsiders, and he runs a business of trading the blood of young children in exchange for food and resources with the citadels. Vesper, too, has had to give her blood to get some minor help from her uncle once or twice, but she denies turning into a blood-breeding machine for Jonas.

One day, while sneaking around Jonas farm in search of food and medicine, Vesper gets hold of a great treasureshe manages to enter a room full of seeds that Jonas had received from the citadel and steals a few of them. On her way out, though, she also spots a few citadel drones flying in the sky, of which one falls out and crashes, and this poses a new possibility in Vespers young life.

Although Vesper manages to steal the seeds, they are clearly not worth much since they would only yield one harvest, and they would again have to depend on Jonas supply. But in young Vespers mind, she is confident that she will be able to engineer a way to decode the seeds and remove the single-harvest characteristic from them. With this, she plans to approach the citadels and secure a job and residency inside them, and then get her fathers ailment treated. All these plans keep buzzing in her head when she goes out the next day in search of more supplies. She spots a young woman lying unconscious in the forest and brings her back to her house. Vesper treats her back to health, and the woman is introduced as a member of the rich society living inside the nearest citadel. Camellia, as she is called, regains consciousness and looks for a man who had been inside the drone when it crashed. She tells Vesper that the missing man is her father, Elias, and offers to help the young girl and her father if she helps her find him. Camellia herself seems to possess special powers, as she can calm down and put one to sleep instantly with a kiss, as she does to Darius one night when he struggles with his pains.

On the other side, Vesper goes through the forest looking for the crashed drone and finds it too, but before she can rescue the trapped man inside, Jonas and his cult of children join her. They strip open the drone, and Jonas murders Elias and then collects whatever useful material they can find on him and the drone. Vesper returns home disheartened, but she does not tell Camellia anything about her fathers death. The young girl soon develops a bond with the woman, and she even takes her to see the countless different experiments Vesper had done and their results. Camellia also grows affectionate towards Vesper and learns more about her parents and their lives. But all things come to a sharp halt when Vesper is one day caught sneaking around Jonas farm. The cruel uncle had been suspecting that Vesper was stealing his germinating seeds, and now he confronts her. Vesper tries to run away but is intercepted by the children of the cult inside the forest, and they brand her with Jonas mark, meaning that she is considered part of the blood-selling group from now on. She runs back home and is comforted by Camellia, and now Vesper cannot help but reveal the truth that she has been keeping hidden for so long. She tells Camellia about her fathers fate and even takes her to the place where Jonas had thrown the mans body, and Camellia has an outburst of grief and anguish. She now makes revelations of her own and tells Vesper that she is not a real human being but is instead a Jug, an artificial humanoid that people inside the citadels create to keep them as workers, almost like slaves. Despite it being a major crime to create a Jug with human-like intelligence, Elias had created Camellia exactly like a human being and had kept her safe for so long. But, her true nature had been revealed, and she and her father, therefore, had to escape from the citadel. They had indeed been escaping the citadel in their drone and were being chased by the authoritarian drones when their vehicle crashed, and they landed in the outside wastelands.

Hearing all this, Vesper realizes that her plan of escaping to the citadels with Camellias help is never an option, and she throws a childish fit at the woman. This further affects Camellia, and even though Vesper gets over her grief in some time, Camellia has a tougher time dealing with hers, and she tries to kill herself. Vesper intervenes, and then she asks Camellia if she could study a sample of her, and the woman agrees to let her do it. While researching the humanoids genetic sample, Vesper finally makes an immense breakthrough. She realizes that the real reason Elias had made Camellia was to hide inside her the secret to breaking the code of seeds yielding only a single harvest. When they had escaped their citadel, Elias had already made an agreement with a different citadel where they were promised safe shelter in exchange for Elias engineering masterpiece. Vesper now learns of it and immediately starts off to gather ingredients for her new research. However, Jonas visits her house in the meantime and finds Camellia there, and he also quickly learns that the woman is a Jug. Vesper returns and stops the man from causing any serious harm, and the two women take control of the situation. Although they can kill Jonas, Vesper decides to let him go
instead and even treats the wounds he incurred. Before setting him free, the young girl tells him that she wants to make a deal with the citadels and would therefore want him to contact them. But Jonas seems to have something else in mind. As a man regularly trading with the citadels, he does have direct contacts there, and he does get in touch with them too, but only to inform them that he knows the location of Camellia, the Jug they have been looking for.

Much like most other things in the film, the character of Vesper is a fine balance between emotions and intelligence. From early on, she yearns for love and affection. She desires to have a family. The young girl still does not understand why her mother had left them, and she even has a close affection for a dead, unmoving human skeleton inside their old laboratory. It is because of this yearning that she takes Camellia into her life very quickly and opens up to her so easily. Perhaps the womans age makes her a good fit to be Vespers elder sister or young mother. In the end, when Vesper declines to kill Jonas, it is perhaps because the man is her uncle, her own blood tie, even though he had never wanted any good for them. On the other hand, Vesper is also not emotional enough to immediately use the power of her knowledge to help everyone around her. She decides to take the seeds and the new science she has learned to the citadel because, after all, she wants personal favorsto cure her fathers sickness.

The citadel police quickly arrive at the wasteland settlement, and the very first thing they do is cruelly shoot their informer, Jonas, dead. Knowing well that there was no way to avoid the citadel police force, Darius convinces Vesper and Camellia to escape the house and hide in the swamps while he distracts the police and sends them some other way. The girl reluctantly agrees and goes to the swamps, from where she painstakingly sees her house, and therefore her father, get blown to bits. Two of the personnel chase them inside the swamp too, and ultimately, Camellia decides to surrender herself to the police in order to save Vesper. The young girl continually pleads with her not to do so, not to leave her completely alone, but the more mature Camellia perhaps realizes the worth of Vesper to the world if she lives. With a kiss, she puts Vesper to sleep and then turns herself in; although her fate is not shown or mentioned, it is most likely that Camellia is immediately killed in the citadel.

The next morning, Vesper wakes up and finds herself all alone in the woods. She returns to her house, which is just debris now and plants three of the genetically modified seeds in the ground. Hearing scuffling noises, Vesper looks up to see that some of the children who had been part of Jonas cult are now following her since their leader is now dead. She walks across the vast barren land, clearly looking for something, and the kids follow her around. Gradually they become a group, and they come across the pilgrims, and Vesper now follows them to their camp. She had, in fact, always wanted to follow pilgrims to find out where they went, and now she sees that they have built a giant tower in the middle of the forest with all the scavenged wood and metal pieces. Vesper climbs up the tower and sees the citadels in the distance. Perhaps knowing too well that there was no need for any personal favors now since she had lost her father and also everyone else, Vesper decides to let the seeds go into the air, where they will naturally grow into new life wherever they land. A sad tale of loss and suffering thus ends with a bright ray of hope. Even though she could not perhaps save her own dream, Vesper compensates it with the dream of a new world with no shortage of food and supply.

Vesper is a 2022 drama science fiction film directed by Kristina Buozyte and Bruno Samper.

Read the rest here:
'Vesper' Ending, Explained: What Happens To Vesper And Camellia? What Does He Do With The Seeds? | DMT - DMT

Studying yeast DNA in space may help protect astronauts from cosmic radiation – The Conversation

Nuclear fusion reactions in the sun are the source of heat and light we receive on Earth. These reactions release a massive amount of cosmic radiation including x-rays and gamma rays and charged particles that can be harmful for any living organisms.

Life on Earth has been protected thanks to a magnetic field that forces charged particles to bounce from pole to pole as well as an atmosphere that filters harmful radiation.

During space travel, however, it is a different situation. To find out what happens in a cell when travelling in outer space, scientists are sending bakers yeast to the moon as part of NASAs Artemis 1 mission.

Read more: Artemis 1: how this 2022 lunar mission will pave the way for a human return to the Moon

Cosmic radiation can damage cell DNA, significantly increasing human risk of neurodegenerative disorders and fatal diseases, like cancer. Because the International Space Station (ISS) is located in one of two of Earths Van Allen radiation belts which provides a safe zone astronauts are not exposed too much. Astronauts in the ISS experience microgravity, however, which is another stress that can dramatically change cell physiology.

As NASA is planning to send astronauts to the moon, and later on to Mars, these environmental stresses become more challenging.

Read more: Twins in space: How space travel affects gene expression

The most common strategy to protect astronauts from the negative effects of cosmic rays is to physically shield them using state-of-the-art materials.

Several studies show that hibernators are more resistant to high doses of radiation, and some scholars have suggested the use of synthetic or induced torpor during space missions to protect astronauts.

Another way to protect life from cosmic rays is studying extremophiles organisms that can remarkably tolerate environmental stresses. Tardigrades, for instance, are micro-animals that have shown an astonishing resistance to a number of stresses, including harmful radiation. This unusual sturdiness stems from a class of proteins known as tardigrade-specific proteins.

Under the supervision of molecular biologist Corey Nislow, I use bakers yeast, Saccharomyces cerevisiae, to study cosmic DNA damage stress. We are participating in NASAs Artemis 1 mission, where our collection of yeast cells will travel to the moon and back in the Orion spacecraft for 42 days.

This collection contains about 6,000 bar-coded strains of yeast, where in each strain, one gene is deleted. When exposed to the environment in space, those strains would begin to lag if deletion of a specific gene affects cell growth and replication.

My primary project at Nislow lab is genetically engineering yeast cells to make them express tardigrade-specific proteins. We can then study how those proteins can alter the physiology of cells and their resistance to environmental stresses most importantly radiation with the hope that such information would come in handy when scientists try to engineer mammals with these proteins.

When the mission is completed and we receive our samples back, using the barcodes, the number of each strain could be counted to identify genes and gene pathways essential for surviving damage induced by cosmic radiation.

Yeast has long served as a model organism in DNA damage studies, which means there is solid background knowledge about the mechanisms in yeast that respond to DNA-damaging agents. Most of the yeast genes playing roles in DNA damage response have been well studied.

Despite the differences in genetic complexity between yeast and humans, the function of most genes involved in DNA replication and DNA damage response have remained so conserved between the two that we can obtain a great deal of information about human cells DNA damage response by studying yeast.

Furthermore, the simplicity of yeast cells compared to human cells (yeast has 6,000 genes while we have more than 20,000 genes) allows us to draw more solid conclusions.

And in yeast studies, it is possible to automate the whole process of feeding the cells and stopping their growth in an electronic apparatus the size of a shoe box, whereas culturing mammalian cells requires more room in the spacecraft and far more complex machinery.

Such studies are essential to understand how astronauts bodies can cope with long-term space missions, and to develop effective countermeasures. Once we identify the genes playing key roles in surviving cosmic radiation and microgravity, wed be able to look for drugs or treatments that could help boost the cells durability to withstand such stresses.

We could then test them in other models (such as mice) before actually applying them to astronauts. This knowledge might also be potentially useful for growing plants beyond Earth.

Read more from the original source:
Studying yeast DNA in space may help protect astronauts from cosmic radiation - The Conversation

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 – Investing News Network

As announced in February 2022, the trial was stopped prematurely due to COVID-19 pandemic operational challenges, limiting enrollment to 73 out of the 150 planned participants. Due to the limited enrollment, the threshold for significance was pre-specified at p=0.10 prior to database lock. The primary analysis was conducted in a modified intent to treat (mITT) population, which censored invalid data. The mITT population excluded data from a single site (n=9) with LCLA testing execution errors and the timed 25-foot walk data from one subject with a change in mobility assist device. The ITT results were directionally consistent with the mITT results, although the ITT results were not significant.

"These data are very encouraging to us in the MS research and treatment community as we work to address functional improvement in patients," said Benjamin Greenberg, MD, MHS, FANA, FAAN, CRND Professor of Neurology and one of the trial's clinical advisors. "The MS community has been successful at limiting relapses, but we need therapies to address progression independent of relapse activity (PIRA). This study was designed as a proof-of-concept evaluation to establish that treatment of neuronal and glial energetic failure can support remyelination and neuroprotection in people living with MS. I am pleased to see the potential effectiveness of CNM-Au8 demonstrated in this trial."

Primary and secondary results from Baseline to Week 48 were:

Consistent improvements favoring CNM-Au8 were observed across multiple paraclinical biomarkers, including multifocal visual evoked potentials (mfVEP) amplitude and latency, optical coherence tomography (OCT), and MRI endpoints, including magnetization transfer ratio and diffusion tensor imaging metrics. Placebo treated patients, in contrast, generally worsened as expected across these measures during the 48-week period. These data provide independently assessed quantitative physiological evidence that supports the potential neuroprotective and remyelinating effects of CNM-Au8. The full dataset will be reported at an upcoming scientific congress.

CNM-Au8 was well-tolerated, and there were no significant safety findings reported.

Robert Glanzman, MD, FAAN, Clene's Chief Medical Officer, said, "In this study, CNM-Au8 demonstrated neurological improvements in people with stable relapsing MS as adjunctive therapy to immunomodulatory DMTs. I am very impressed by the consistency of structural and functional improvements demonstrated by CNM-Au8 throughout the neuraxis. With these data, Clene looks forward to initiating a Phase 3 clinical program in people with MS who are experiencing progression independent of relapse activity, the most urgent unmet medical need in MS today. We look forward to the next phase of clinical development."

Rob Etherington, Clene's Chief Executive Officer and President, added, "These results further demonstrate the potential of CNM-Au8 to drive neuronal cellular energy production in patients struggling with MS and other neurodegenerative diseases. We also await additional evidence of clinical efficacy from the HEALEY ALS Platform Trial, which is expected to report topline data later in this quarter. Clene will continue to work tirelessly to further CNM-Au8's development to treat neurodegenerative diseases."

Conference Call and Webcast Information Clene will host a conference call and webcast at 7:30 am EDT to discuss the VISIONARY-MS topline results.

Toll free: 1 (888) 770-7152 Conference ID: 5318408 Press *1 to ask or withdraw a question, or *0 for operator assistance .

To access the live webcast, please register online at this link . Participants are requested to register at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months. A live audio webcast of the call will be available on the Investors section of the Company's website Presentation page . An archived webcast will be available on the Company's website approximately two hours after the event.

About VISIONARY-MS VISIONARY-MS was a Phase 2 multi-center, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of CNM-Au8 in participants with stable relapsing remitting multiple sclerosis (RRMS) with a history of chronic visual impairment who are allowed disease-modifying therapy (DMT). Enrolled subjects were randomized 1:1:1 to CNM-Au8 15 mg/day, 30 mg/day, or placebo. As announced in February 2022, the trial was stopped prematurely due to COVID-19 pandemic operational challenges, enrolling 73 out of the 150 planned participants. Due to limited enrollment, the threshold for significance was pre-specified at p=0.10 prior to database lock. The primary endpoint was the change in best corrected-low contrast letter acuity (BC-LCLA) from baseline to week 48 in the clinically affected eye. Key secondary efficacy outcomes assessed neurological function by the modified MS Functional Composite (mMSFC) including 25-Foot Timed Walk, Symbol Digit Modalities Test, 9-Hole Peg Test (dominant and non-dominant hands), and LCLA (affected and fellow eye) from baseline through Week 48. For more information, see ClinicalTrials.gov . Identifier: NCT03536559 . The open label extension of VISIONARY-MS is ongoing.

About CNM-Au8 CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is a federally registered trademark of Clene Nanomedicine, Inc.

About Clene Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit http://www.clene.com or follow us on Twitter , LinkedIn and Facebook .

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Clene's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include our ability to demonstrate the efficacy and safety of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Source: Clene Inc.

See the article here:
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Investing News Network

Liquid Biopsy Detects Nano-Sized Signs of Breast Cancer in Early-Stage Patients – Technology Networks

Want FREE access to this Audio Article?

Complete the form below to unlock access to this Audio Article: "Liquid Biopsy Detects Nano-Sized Signs of Breast Cancer in Early-Stage Patients"

A USC-led team of scientists has found indications that a special blood test called a liquid biopsy could determine whether a patient has breast cancer at its early stage and if that cancer is unlikely to return.

These high-definition comprehensive liquid biopsies are conducted using a standard blood draw from the arm of a patient in a doctors office. Once in the laboratory, the sample is examined for signs of cancer.

The study demonstrating the liquid biopsy results for early breast cancer detection was published in Natures npj Breast Cancer journal. The work was a collaboration between USC, Billings Clinic, Duke University, Epic Sciences and USC Norris Comprehensive Cancer Center. The results raise hopes that one day doctors could detect breast cancer in patients with a simple blood draw.

The researchers at the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer) are cautiously optimistic about their findings. They are eager to test and see whether the results will be proven in larger clinical trials to demonstrate the benefit of the method for patients everywhere.

Its an amazing opportunity to change how early breast cancer detection is being done with a simple blood draw, but it's only a research outcome at this point and we still need to demonstrate clinical benefit, said Peter Kuhn, a USC cancer physicist who directs CSI-Cancer.

Breast cancer is the most prevalent form of cancer in the world, affecting 1 in 8 women over their lifetime.

Since 1976 when the American Cancer Society endorsed the technique, mammography X-ray, along with a tissue biopsy, has become the standard way for doctors to check patients for breast cancer.

But mammography is not 100% accurate and its detection can be impeded by healthy dense tissue. Mammographys sensitivity to breast cancer is around 87%, according to the Breast Cancer Surveillance Consortium. And for some women, mammograms are not accessible, especially those living in poor isolated communities that have no clinics or hospitals. Others simply do not get a regular mammogram.

But a tissue biopsy also is not a fool-proof method. Although it can reveal information about the tumor, it has limitations. Doctors can sample only a small area and may fail to capture the full extent of the tumor. A tissue biopsy is also invasive and painful.

Combined, the drawbacks for diagnosis with mammograms and tissue biopsies mean some patients are not diagnosed until the cancer has grown and spread. New methodologies such as CSI-Cancers liquid biopsy can bring a complementary toolset into clinical practice.

For the study, Kuhn and his team worked with 100 breast cancer patients some early and late stage and 40 patients without breast cancer from April 2013 through January 2017. The work was conducted at clinical sites including at the Norris Comprehensive Cancer Center at Keck Medicine of USC, the Billings Clinic in Montana, Duke University Cancer Institute in Durham, North Carolina and the City of Hope Comprehensive Cancer Center in Duarte, Calif.

The team tested a theory that the high-definition liquid biopsy could detect multiple cancer biomarkers, including the so-called oncosomes nano-sized, membraned cargo carriers that enrich the bodys environment for cancer growth. These oncosomes are secreted by cancer cells as the group has shown previously.

The news here is that we found the vast majority of early-stage breast cancer patients have these oncosomes at very robust levels, said Kuhn, a Deans Professor at USC Dornsife College of Letters, Arts and Sciences and cancer physicist. Theyre about 5-10 microns in diameter. About the size of a cell. We first identified these large vesicles in prostate cancer about a year-and-a-half ago and showed that they are related to the cancer. They are hiding in plain sight.

If further studies produce similar results, this could mean that the next generation high-definition liquid biopsy may become a diagnostic tool for early breast cancer detection and other cancers, he said. The test also could inform patients who have been treated for cancer that they will most likely remain cancer-free.

Typically, Im the bearer of bad news. I say, You have cancer in your blood, Kuhn said. But a test like this could give hope that if there is a sign of cancer, we can find it very early and improve treatment and survival.

Reference: Setayesh SM, Hart O, Naghdloo A, et al. Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. npj Breast Cancer. 2022;8(1):1-11. doi: 10.1038/s41523-022-00480-4

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:
Liquid Biopsy Detects Nano-Sized Signs of Breast Cancer in Early-Stage Patients - Technology Networks

Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia – Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-III. This specific indication clearance enhances the CellFX Systems general indication FDA clearance and enables the Company to support clinics in marketing and promoting CellFX treatments specifically for patients with sebaceous hyperplasia. The clearance was based on clinical data from the Companys IDE approved study for the treatment of sebaceous hyperplasia.

The Company also recently received FDA 510(k) clearance of two additional treatment tips with larger spot sizes, specifically 7.5mm and 10mm tip sizes, for treating larger benign lesions. These treatment tips broaden the portfolio of previously available 1.5mm, 2.5mm and 5.0mm treatment tip sizes.

We are pleased with the continued advancement of the CellFX System and its capabilities to enhance its value proposition for patients, clinicians and any potential commercial partner. These clearances provide further validation of the systems strong safety and effectiveness profile, said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences. We would like to thank all of the investigators, the staff at their clinics and the patients who participated in these trials, as well as the FDA for their ongoing collaboration as we endeavor to offer the benefits of NPS technology to more patients.

About Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Companys proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of conditions for which an optimal solution remains unfulfilled. The Company is actively pursuing application development in cardiology, oncology, gastroenterology, and other medical specialties. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit http://www.pulsebiosciences.com to learn more.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences expectations concerning customer adoption and future use of the CellFX System to address a range of dermatologic conditions, statements relating to the Companys future product development in healthcare outside of dermatology and the Companys other activities to develop and commercialize NPS technology to drive growth, statements about the Companys ability to pursue and complete strategic transactions and its prospects to partner any of its programs, whether in dermatology or otherwise, statements relating to the effectiveness of the Companys NPS technology and the CellFX System to improve the quality of life for patients, and Pulse Biosciences expectations, whether stated or implied, regarding whether any regulatory clearances will enhance the value proposition of the CellFX System for patients, clinicians or others, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors. Words such as may, will, could, would, should, anticipate, predict, potential, continue, expects, intends, plans, projects, believes, estimates, and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

See the original post here:
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia - Business Wire

Taubman to Conclude CEO and Dean Terms In December 2023 – URMC

Mark B. Taubman, M.D., URMC CEO and Dean of the School of Medicine and Dentistry, has decided not to seek reappointment upon completion of his terms as CEO and Dean. The 72-year-old URMC leader will hand over the reins on December 31, 2023 or later if a successor has not been identified, as announced by University of Rochester President Sarah Mangelsdorf at todays Board of Trustees meeting.

I have been honored to lead this great institution and am proud of the significant advances we have achieved, particularly over the past two years, Taubman said. With so many of the goals of our strategic plan either accomplished or well underway, the time feels right to begin succession planning to assure our Medical Center is structured for a strong and vibrant future.

Taubman racked up many firsts during his tenure. In 2015, he became the first to serve as both Dean of SMD and URMC CEO. He was the first to create and implement an integrated strategic plan for URMC that stretched across all three missions, re-invigorating the foundations for core patient care, research, and education activities, and significantly boosting commitments to diversity and inclusion efforts. He led a strong and successful faculty leadership recruitment focus, and assured a renewed emphasis on financial agility by establishing the Medical Centers first integrated financial model to recognize its interdependent missions and ensure support for the academic enterprise.

More recently, his steady and reassuring leadership was essential to the Universitys response to the COVID-19 pandemic. He also worked with Monroe County public and health officials to structure a coordinated community plan, and dedicated Medical Center resources to build tools and infrastructure to support screening, testing and eventually equitable distribution of vaccine within the Rochester community and surrounding regions.

Mark has been a visionary leader and a thoughtful, supportive colleague to me and to so many others across the institution, Mangelsdorf said. The fact that he is providing us with ample notice of his future plans so that we can thoughtfully organize and conduct a search for his successor is just another indication of his commitment to the ongoing work of the University and the Medical Center. I am not only grateful for Marks past service; Im also glad that we can count on his continued service for the next 15 months.

Taubman said that he will actively work to conclude many important initiatives currently underway. These include developing local solutions to our nations health care worker shortage, improving the Medical Centers financial performance and growing the research mission. He will also stay focused on finalizing expansion and modernization plans for Strongs Emergency Department and inpatient areas, opening the first phases of UR Medicines Orthopaedics and Physical Performance Center, and lay plans for the future growth of the UR Medicine health system.

A board-certified cardiologist, Taubman came to the Medical Center as chief of the Cardiology Unit and Paul N. Yu Professor in Cardiology in February 2003. He became chair of the Department of Medicine and Charles E. Dewey Professor of Medicine in May 2007, and served in that role until being named as dean. He briefly served as acting CEO in 2010 while former CEO Bradford Berk, M.D. recovered from an injury.

Taubman graduated from the New York University School of Medicine and completed his residency and cardiology fellowship training at the Brigham & Womens Hospital. He held academic appointments at Harvard Medical school, Childrens Hospital Boston, and Mt. Sinai School of Medicine. Prior to being recruited to the University of Rochester, he was director of cardiovascular research at Mt. Sinai.

Go here to see the original:
Taubman to Conclude CEO and Dean Terms In December 2023 - URMC

Becher promoted to Chief Medical Officer at Community Care of West Virginia – My Buckhannon

Buckhannon, W.Va. Dr. Kimberly Becher has been promoted to Chief Medical Officer at Community Care of West Virginia (CCWV), joining the leadership team with more than a decade of experience in the medical industry.

Becher joined CCWV in 2014 as a family physician at Community Cares health center location in Clay.

Kimberly has an extensive background in the medical field and has shown immense passion for her community and issues that face our rural patients, announced Patricia Collett, chief operations officer of Community Care of West Virginia. I am confident that she will make an excellent and vital addition to our leadership team.

Becher has held several leadership positions at the university, state, and national level. As a medical student, she was a member of the American Academy of Family Physicians (AAFP) Commission on Governmental Advocacy. She was selected as a resident spokesperson for the AAFPs 2012 visit to the White House. She served as a resident on the board of directors of the AAFP from 2013 to 2014 and as the New Physician Delegate to the AAFP Congress of Delegates in 2018.

I have dedicated my career to bettering the health and lives of West Virginians and I am excited to take my responsibility to the next level so that we can continue to grow and deliver services that best serve our patients and their whole health needs, said Becher.

Becher acquired her undergraduate degree in biology from Denison University in Granville, Ohio, in 2002. She received her medical degree from Marshall University Joan C. Edwards School of Medicine in 2011 where she also completed her family medicine residency and served as one of the departments chief residents. Between her undergraduate studies and medical school, Dr. Becher carried out breast and colon cancer research at the University of Cincinnati.

As we continue to grow and expand our services, Dr. Becher has the vision and expertise to lead us into this next phase as our new chief medical officer, stated Collett.

Becher grew up in West Virginia and is an active member of her community. She has served as a volunteer physician at the Marshall Medical Outreach homeless clinic and as a volunteer at the Health Sciences and Technology Academy of West Virginia University summer camp. She also served on the Mountaineer Food Banks board of directors from 2018 to 2021 and continues to be on the Clay Senior and Community Services board.

View post:
Becher promoted to Chief Medical Officer at Community Care of West Virginia - My Buckhannon

A Plea for Campus Unity in the New Year – The Commentator – The Commentator

As members of YUs undergraduate faculty, we believe it is our duty to speak up when the well-being of our students is put in jeopardy. We are also deeply invested in ensuring that our university is regarded highly in the broader academic world and in promoting its public standing. It is clear that the actions of the YU administration against the Pride Alliance are causing great harm to our LGBTQ+ students and community members. It is also our sincere belief that these actions have the potential to harm the entire undergraduate student body, by damaging YUs status as a premier institution of higher education, having recently risen in The US News and World Reports rankings.

Some members of our community may be hesitant to wade into this issue because they believe it does not directly involve them. We especially worry that our undergraduate students are not fully aware of the damage being done to YUs reputation as a university. Students should know that this threat to YUs reputation is real. Faculty and administrators from many of YUs own graduate programs as well as its affiliated medical school and hospital have already spoken out against YUs measures. In addition to the letter signed by over eighty members of the undergraduate faculty, faculty from the Cardozo School of Law, Ferkauf Graduate School of Psychology, Wurzweiler School of Social Work as well as Albert Einstein College of Medicine and Montefiore Hospital have written open letters of protest, as have Cardozos Board of Overseers. The Bernard Revel Graduate School of Jewish Studies posted a statement on their website, and students at Cardozo and Ferkauf staged a walkout on September 21. As of this writing, more than 1700 alumni and community members have signed a heartfelt letter of protest. Even more recently, the Wilf family, whose name adorns our Washington Heights campus, stated that they strongly disagree with YUs decision. Moreover, there has been widespread coverage of this issue, especially the Universitys decision to cancel all clubs, in mainstream publications such as The Wall Street Journal, CNN, The New York Times, Reuters, NPR, Politico, the New York Post and more.

Through their public litigation, the University risks undermining our reputation in the wider world. We are concerned that this unfortunate development has the potential to limit students' career paths and graduate school admissions prospects, including law school, medical school and other professional schools. It also threatens harm to the universitys own fundraising efforts to support important programming. Faculty may struggle to keep, renew or obtain the federal grants that support their research and especially their labs, which, in turn, are essential to both students graduate admissions and internships in industry. Competitive academic programs throughout the country value equality and non-discrimination toward LGBTQ+ students, and may judge YU undergraduate programs that publicly challenge these core principles. Future employers may be similarly reluctant to hire students from a university that discriminates and does not recognize its LGBTQ+ students equality.

This damage to YUs reputation is in addition to the harm that is being done to our LGBTQ+ students right now. Our university of which we are all a part is implicitly telling these students that they are not of equal value to other students who are allowed to form and join clubs based on their identities. Our colleagues at Ferkauf, Wurzweiler, and Einstein have written in depth about the potential harm these legal actions can cause our LGBTQ+ students and their allies in terms of mental health and ability to thrive. In addition, the universitys actions adversely influence their ability to learn in our classes and take advantage of all YU has to offer. We invite you to read the YU Pride Alliances overview of the case to better understand what they are asking for.

We hope that our students will not only show compassion to their classmates but also stand up for their own interests and future prospects by speaking out against these legal actions. While the Pride Alliance has granted YU the legal stay requested so that other student clubs can resume, there is still time for the University to choose a path of unity. The University can withdraw its appeal or reach another resolution and prevent Yeshiva University vs Pride from becoming shorthand across the United States for legal discrimination against LGBTQ+ students. As we enter the new year, now is the time to put aside differences and come together in what we know to be our shared values. As the Revel faculty put it in their recent statement, it is our imperative as members of this university to recognize the dignity and respect with which we should all treat our fellow human beings.

With best wishes to all for a sweet new year,

Tamar Avnet, Professor of Marketing, Sy Syms School of Business

James Camara, Clinical Associate Professor of Chemistry, Yeshiva College

Anna Lisa Cohen, Professor of Psychology, Yeshiva College

Gabriel Cwilich, Professor of Physics, Yeshiva College

Lauren Fitzgerald, Professor of English, Yeshiva College

Jeffrey Freedman, Professor of History, Yeshiva College & Stern College

Sumanta Goswami, Associate Professor of Biology, Yeshiva College

Jenny Isaacs, Associate Professor of Psychology, Yeshiva College

David Lavinksy, Associate Professor of English, Yeshiva College

Rachel Mesch, Professor of English, Yeshiva College

Jess Olson, Associate Professor of Jewish History, Yeshiva College & Stern College

Raji Viswanathan, Professor of Chemistry, Yeshiva College

For more articles like this,join us on WhatsApp.

Link:
A Plea for Campus Unity in the New Year - The Commentator - The Commentator

Program Will Fund Genomics Research at Historically Black Medical Colleges – Healthcare Innovation

The Accelerate Precision Health program will award $46 million total in funding, or $11.5 million per institution, over the next five years to four Historically Black Medical Colleges (HBMCs) to support the scientific research they are doing to address significant gaps in genomics research.

The Chan Zuckerberg Initiative (CZI) program will seek to advance genomics research by investing in genomics programs at Charles Drew University College of Medicine in Los Angeles; Howard University College of Medicine in Washington, D.C.; Meharry Medical College in Nashville; and Morehouse School of Medicine in Atlanta.

Through the partnership, the HBMCs will expand research opportunities for undergraduate, graduate, and post-doctoral students; support the creation of a new Master of Science program in Genetic Counseling; support recruitment of anchor faculty in genomics; and fund state-of-the-art tools for data handling, storage, and analysis, among other elements.

Its important to underscore that for Black Americans, there is a large gap between representation and need in genomics research, and the time is now to support the intersection of genomics and health differences research that will advance science. Research shows that expanding representation leads to innovative discoveries, said CZIs Senior Science Advisor Hannah Valantine, in a statement. Actively engaging HBMCs and the communities they serve in genomics research is a necessary approach to harness new perspectives that will fuel creative interdisciplinary research, unleash innovations that have yet to be conceived, and accelerate precision health equity.

Morehouse School of Medicine is thrilled to partner with the Chan Zuckerberg Initiative on the Accelerate Precision Health program, said Morehouse School of Medicine President and CEO Valerie Montgomery Rice, M.D., in a statement. CZI support will allow MSM to expand our educational programs and our world-class genomics research enterprise simultaneously. Through this partnership, MSM will train more graduate students and postdoctoral fellows, hire additional research scientists, and establish an endowed faculty position funded by CZI. These measures will enhance Morehouse School of Medicines continued commitment to academic excellence, service, and innovation as we lead the creation and advancement of health equity.

This grant is part of a multi-year, $500 million investment CZI announced in December 2020 to support organizations leading the way to advance racial equity, diversity and inclusion efforts.

Read the rest here:
Program Will Fund Genomics Research at Historically Black Medical Colleges - Healthcare Innovation

Parents are so wrong about teenage sleep and health – Harvard Gazette

As a new school year begins, Harvard-affiliated sleep health researchers have a message for parents and caregivers on teenage sleep: youre wrong.

A study by investigators from Brigham and Womens Hospital enlisted experts in adolescent sleep to identify myths. Researchers then surveyed parents and caregivers, finding that more than two-thirds believed in the top three most salient myths about sleep. These involved school start times, the safety of melatonin, and the effects of altered sleep patterns on the weekends. In their new paper, published in Sleep Health, the authors explore the prevalence of each myth and present counterevidence to clarify whats best for health.

Adolescents face myriad barriers when it comes to sleep, some of which are physiological and others behavioral, said corresponding author Rebecca Robbins, a researcher in the Brighams Division of Sleep and Circadian Disorders and a Harvard Medical School instructor. Given these challenges, it is critical to reduce any modifiable barriers that stand in the way for young people when it comes to sleep. Our goal was to identify common adolescent sleep myths and inspire future public outreach and education efforts to promote evidence-based beliefs about sleep health.

Caregivers and adolescents commonly turn to the Internet and social media for guidance on topics such as sleep. Although these platforms can be sources of evidence-based information, there is the chance that misinformation can proliferate on these platforms.

The researchers surveyed 200 parents and caregivers about 10 sleep myths identified by experts. Some of the prevalent myths that Robbins and colleagues identified and deconstructed include:

Approximately 74 percent of parents/caregivers agreed with this myth. But, the researchers explain, varying sleep schedules on the weekend also known as social jetlag can worsen sleep and does not restore sleep deficits. The authors cite studies showing that varying sleep schedules on the weekend can lead to lower academic performance, risky behaviors such as excessive alcohol consumption, and increased mental health symptoms.

About 69 percent of parents/caregivers agreed with this myth. Robbins and colleagues cite numerous studies showing that delayed middle and high school start times resulted in significantly more sleep, with extended sleep in the morning and minimal impact on bedtimes.

Two-thirds of parents/caregivers believed this myth. While melatonin has become a common supplement for adults and adolescents, longer-term studies on its use are lacking, particularly when it comes to melatonins effects on puberty and development. The content of melatonin in supplements varies widely. The authors also raise concerns about teens taking melatonin without medical evaluation or supervision, and without using behavioral interventions to help address insomnia.

The authors note that their study explored sleep myths among a small sample of parents/caregivers, and future studies of a larger population of parents/caregivers may help to further clarify sleep beliefs. Future studies could also include adolescents themselves as well as experts from other countries and cultures.

Future research should aim to counter myths and promote evidence-based beliefs about adolescent sleep, said senior author Judith Owens, a Boston Childrens Hospital physician and a professor of neurology as Harvard Medical School.

Disclosures: Robbins has served as a consultant to Denihan Hospitality Group, SleepCycle AB, Rituals Cosmetics BV, Deep Inc., and Wave Sleep Inc. Co-author Lauren Hale received an honorarium from the National Sleep Foundation for her role as editor in chief of Sleep Health (between 2015 and 2020). Co-author Michael Grandner has received grants from Kemin Foods, Jazz Pharmaceuticals, and CereZ Technologies, and has received consulting funds from Fitbit, Natrol, Casper, Athleta, and Merck.

Funding: Funding for this work was provided by the NIH/National Heart, Lung and Blood Institute, National Institutes of Health, and the Department of Defense.

Sign up for daily emails to get the latest Harvardnews.

Read the rest here:
Parents are so wrong about teenage sleep and health - Harvard Gazette

New International Partnership to Tackle Public Health Challenges – University of Arizona

The University of Arizona Mel and Enid Zuckerman College of Public Health and the University of Limerick School of Medicines Master of Science Public Health program in Ireland have entered into an International Memorandum of Agreement to enhance cooperation in research and academics.

The partnership will focus on areas of mutual interest through research collaboration, faculty, scholar and student exchanges, direct enrollment and study abroad programs.

In August 2021, Gabriela Valdez, PhD, director of global education and assistant professor in the Zuckerman College of Public Health, and Niamh Cummins, PhD, lecturer in the School of Medicine at the University of Limerick, began crafting an agreement. The strategic goal of the partnership is to advance public health education, research and practice to address the health needs of diverse populations in both countries.

We are pleased to partner with the University of Limerick, especially as we both see the benefits of applied public health education, said Iman Hakim, MD, PhD, dean of the Zuckerman College of Public Health. I want to thank Dr. Valdez and Dr. Cummins for all the work they did to bring our institutions together for the greater good of public health.

The initial collaboration will focus on exchanges of faculty and scholars for short- and long-term visits. The programs plan to collaborate on research, including developing formal research funding proposals.

Megan Bounds, a second-year graduate student in the Zuckerman College of Public Health, was the first student to participate in a research program at the University of Limerick this summer as part of the partnership. Bounds said she is passionate about incorporating public health into medicine and hopes to attend medical school in the future.

My time in Ireland was life-changing, Bounds said. I appreciated the University of Limericks help involving me in many opportunities on campus and around Ireland. They truly took an interest in and enhanced my experience abroad, taking into account my long-term interests and goals.

Those experiences included working at the University of Limerick hospital, meeting with graduate entry medical students and touring the universitys medical facility.

Overall, the Irish people were some of the most kind and welcoming people I have ever met, she added.

In alignment with the partnership, the School of Medicine at the University of Limerick now offers an annualFulbright Scholarship opportunityto a U.S. student, including graduates from the Zuckerman College of Public Health.The Fulbright scholarship will allow one student to complete a fully funded masters in public health at the University of Limerick, which offers a student-centered learning model with an emphasis on community and collaborative learning. The program aims to move from a traditional public health teaching model to a more applied approach to public health education.

The Fulbright scholarship covers the costs of tuition and a student stipend for a 12-month period. The deadline to apply isOct. 11. For more information, visit the Fulbright website. To apply, visit the University of Limerick website or emailmph@ul.ie.

More:
New International Partnership to Tackle Public Health Challenges - University of Arizona

Coast Guard will begin new physician training to help staff clinics – MyCG

The Coast Guard will begin training its own physicians to help fill vacancies in medical staff amidst a nationwide shortage of health care professionals.

The service is expanding two programs that would sponsor Coast Guard members through medical school at the Uniformed Services University of Health Services School of Medicine (USUHS SOM):

The Coast Guard currently has two commissioned officers attending USUHS as medical students. The plan is to have four Coast Guard members begin medical school training and one Coast Guard enlisted member begin premed training in the 2023 academic year.

Selection is a two-step process: 1. Applying to a Coast Guard selection panel (which will include an interview), 2. Applying to USUHS or EMPD2. You can find application packages and other required information on the USUHS admissions page. Email your completed application materials as one PDF package, to Capt. Shane Steiner no later than Oct. 12. More details and requirements are in the Solicitation for 2023 Physician Training Applications ALCOAST 354-22.

The physician training program is part of a wider effort by the Coast Guard to meet its need for health service officers particularly, doctors and dentists as supply tightens and seasoned practitioners separate from the service. In the Commandants Intent, Adm. Linda Fagan directed the enterprise to establish new ways of accessing, training, and developing active duty medical doctors and dentists. On Aug. 5, the Coast Guard began direct commissioning of health service officers.

Previously, the Coast Guard had relied solely on Public Health Service (PHS) Officers to fill medical, dental, and other healthcare positions. A nationwide doctor shortage, exacerbated by the pandemic, has made it necessary for the service to look for additional ways to meet its healthcare needs.

The goal is to have a sustainable model for filling positions, said Rear Adm. Dana Thomas, Director of Health, Safety and Work-Life at CG-11. The U.S. was in a bad situation regarding primary care access before the pandemic. We have experienced a graying of medicine nationally many older providers, not enough younger docs to replace them. Post COVID-19, the situation has worsened. Looking at our Coast Guard physicians, 75% can or will be retired in the next five years.

The Coast Guard is also looking into getting authority to create a Coast Guard Health Service Officer Corps (HSOC) through a Legislative Change Proposal (LCP). This would allow the Coast Guard to manage the careers of Coast Guard Health Services Officers similar to how they are managed in the other Armed Forces such as separate promotion lists that do not count against Coast Guard active or reserve controlled-grade promotion strength or opportunity.

This is a life or death situation, Thomas said. Having the doctors we need determines whether our people are safe to fly, safe to be on a cutter, safe to do any mission. It also determines whether they can do those missions knowing their families are taken care of. In the future the Coast Guard may also need to provide care to our family members in remote locations.

Resources:

Read the rest here:
Coast Guard will begin new physician training to help staff clinics - MyCG

OU medical students fear state legislation will further restrict access to comprehensive reproductive education – The Oklahoma Daily

When longtime Oklahoma resident Christen Jarshaw joined the OU College of Medicines class of 2023, she knew the limitations she would encounter as a studying provider with interests in OB-GYN.

She stayed in state because she wanted to improve Oklahomas 1,630-to-1 patient-to-provider ratio and increase access to reproductive health care in a state burdened by uncomprehensive sex education and the fourth highest maternal mortality rate in the U.S., as of 2018.

Jarshaw, who is in her first year of clinical training, is among OU medical and pre-med students who are considering leaving Oklahoma to expand their education on reproductive health care. But the reasons behind their applications to out-of-state medical schools and residencies are more complicated than the overturning of Roe v. Wade.

Laws like House Bill 4327 and Senate Bill 1503 which allow anyone to sue someone who provides abortions or aids and abets someone in accessing abortion limit OU medical students opportunities to counsel patients. But their ability to learn how to provide abortions has already been restricted by state funding to cases of rape, incest and threats to maternal life for many years.

The hands of faculty from the OU College of Medicine have long been tied by legislative framework inhibiting what they can teach about abortions. For many soon-to-be physicians in Oklahoma, the Dobbs v. Jackson decision was the final straw.

OU Medical Students for Choice on August 24.

The OU College of Medicines curriculum is split into preclinical for the first two years of medical school and clinical training for the remaining two. Jarshaw said medical students take their first course about reproduction in the second semester of their second year of preclinical curriculum.

The course is designed to teach undergraduate medical students about the normal and abnormal structure, function and development of male and female reproductive systems with an emphasis on treatment options for conditions and functions that are specific to women, according to the college of medicines curriculum.

Alexandra Regens, an OB-GYN resident physician at the OU Health Sciences Center who helps organize curriculum on reproductive topics, said she doesnt expect the overturning of Roe v. Wade to impact what she can include in the courses curriculum. She said its impossible to talk about reproductive health care without including conversations on abortion and abortion access.

But beyond this course, Jarshaw said state legislation already prevented medical students interested in abortion care from effectively furthering their education at OU, causing many to either lobby for an expansion of curriculum or look outside the traditional medical system.

For Jarshaw, this was not an issue. She joined OUHSC Medical Students for Choice during her first year and serves as the groups co-president. There, she participates in educational events and lobbies alongside her peers for more comprehensive education.

She also volunteered in less restrictive medical facilities outside OU to further her skills in obstetrics and gynecology. But the overturning of Roe v. Wade limits Jarshaws access to opportunities outside of medical school, meaning she has to rely on clinical training in a space whose services were already limited by state funding.

Regens, who is also the associate clerkship director for third-year medical students, said students entering clinical training will experience the greatest impacts on their learning, as the universitys clinic can only provide abortions in cases threatening maternal life.

Before the overturning of Roe v. Wade, providers in the college could also counsel patients and connect them to external resources. Now, because Oklahoma prohibits anyone from aiding or abetting someone in accessing abortion, they are limited in how they can guide patients.

The need for abortion care exists, Jarshaw said, as patients carrying unwanted pregnancies have made it to the doors of OU's clinic. If the political landscape looked different, Jarshaw could implement the counseling skills she learned from OU or outside involvements.

Christen Jarshaw attending a protest at the Oklahoma state Capitol after the overturning of Roe v. Wade. She is co-president of OUHSC Medical Students for Choice.

The frustration shared between patients and providers is apparent in moments of silence, Jarshaw said, as she and her patients take deep, deliberate breaths. She said it feels like a disservice to know clinical guidelines but be prohibited from following them in ways that would align with everyones experience and morals.

I think everyone across the board is incredibly dissatisfied and upset with the concept that the government is determining what we can and cant say to our patients, Jarshaw said. The patient-and-provider relationship is no longer private and sacred.

Now, Jarshaw is considering whether her studies will continue at OU as she applies for residencies. A close adviser encouraged her to try studying out of state, but she doesnt know where she could go.

Its a reality many current and future medical students face at OU.

OU Health Communications Director April Sandefer wrote in an email to the Daily that, as an academic health system, OU Health provides comprehensive care for women and children of all ages and at all stages of life. She wrote that their health care complies with state and federal laws along with health care regulations and compliance, and they will continue to monitor state and federal legislation and legal changes and ensure full alignment as new laws are enacted.

Some OU pre-med and medical students dont want to wait for legislation to change and are considering other options while they are earlier in their education.

Danielle Digoy, a second-year preclinical medical student, became passionate about reproductive care because of her grandma, who died from cervical cancer when she was in middle school.

Although she is not set on a specialty, Digoy enjoys shadowing OB-GYNs and participates in OUHSC Medical Students for Choice to further her education on reproductive health. She even volunteered at Oklahoma Citys Trust Women Clinic for a few weeks before it shut down.

Oklahoma is where Digoys family lives and where she has planned to stay in the long term, but she fears she will have to travel out of state to continue learning how to provide comprehensive care in abortion provision and counseling.

The state already faces a shortage of OB-GYNs, and Digoy fears the patient-to-provider ratio will continue to shrink if medical students feel they cant access comprehensive education.

We need people who feel this obligation, provide high-quality patient care and provide for their patients and advocate for them, Digoy said. We don't want them all to leave.

Megan Talbot, a biology pre-med senior, is a peer health educator at the OU Goddard Health Center and participates in OU Womens Health Advocacy, a group focused on increasing campus awareness of womens health, tackling stigma and easing access, according to its Instagram page. Both involvements have expanded her interest in OB-GYN by providing spaces for students to discuss and learn about reproductive health care.

Talbot also faces the reality that if she applies to medical school in Oklahoma, she will experience limitations in what she can study. She said she is applying to medical schools in California to receive a comprehensive education.

An OU Physicians white coat with a stethoscope in the shape of a uterus.

Physician shortages and patient needs are both things Talbot said she is keeping in mind, but she wonders how the state can expect her to stay when they are limiting how she could care for Oklahomans.

Luckily, I have more time, but even when I'm looking at medical schools it's very limited because, also as a person of color, I don't want to stay here, Talbot said. I want to go somewhere where I can learn the full scope of medicine and not be limited in my education as a provider because should there come a day where abortion is totally fine, I want to be able to provide that medical care, if necessary.

Regens said she doesnt blame medical students for wanting to leave Oklahoma when there are legal, financial and criminal repercussions for physicians, but that the states continued shortage of providers has the potential to be very dangerous.

Our best shot is the people who are from here, people who have trained here and people who have ties to the state. Its not a time that I would think a lot of physicians from our state are wanting to come here, Regens said.

Outside of Oklahoma, there are 21 states where there is expanded or protected access to abortion, according to the Center for Reproductive Rights. The closest options for students in Oklahoma seeking more comprehensive abortion education are in Kansas and Colorado.

At the University of Colorado Anschutz Medical Campus, providers operate under statutory protections, meaning abortions at any stage of pregnancy are protected as a fundamental right. Michael Belmonte, the colleges senior fellow in complex family planning, chose to work and educate residents in Colorado for this reason.

Belmonte came to Colorado after he completed a residencyat Indiana University, where he could only perform abortions in cases threatening maternal life. Now, he can effectively perform abortions up to 24 weeks and, in certain cases, beyond that.

The universitys educational programs usually include upper-level medical students and residents in the operating room. Starting as early as their first year in residency, students build up basic surgical skills and enter their second year feeling comfortable providing first-trimester abortions.

Belmonte had to wait until the end of his residency in Indiana to provide first-term abortions. He said Colorado students ability to learn how to perform these procedures and counsel patients early helps decrease the stigma felt by the provider and patient.

It really normalizes abortion and makes it a health care decision that you come to with your medical provider and, because of the lack of barriers here, that can start the same day that you decide that this is what you want to do. Being able to support our patients in any choice that they make and doing my best to make that as comfortable and seamless as possible is a really nice change, Belmonte said.

In light of restrictions placed in other states, Belmonte said the universitys clinic has seen more demand. It began with the passage of Texas near-total abortion ban and has only increased with the overturning of Roe v. Wade.

Belmontesaid he wassurprised to hear just how far people need to travel,as its difficult to track down clinics with available appointments, even if a patient lives near a state with fewer restrictions.

Belmonte said he cant fully quantify how many people they see each day, as that number fluctuates depending on circumstances, but there have been moments where their phones were ringing off the hook. A high patient load means students receive a lot of training opportunities, but he said its unfortunately at the expense of their patients difficult circumstances.

Looking ahead, Belmonte said there have been conversations at the University of Colorado about how to open opportunities to medical students, residents and fellows studying in programs restricted by state laws.

It would be logistically challenging, Belmonte said, as there would have to be contracts written between universities, and students would need malpractice insurance. Partnering universities would also have to decide who would pay for expenses like lodging and traveling.

As a former medical resident in Indiana, Belmonte recognizes the considerations and restrictions medical students in states like Oklahoma are experiencing. He said hes felt intimated by anti-abortion advocates, who have sent him anonymous letters and followed him home.

He said he knows hes privileged to practice in an accepting and supportive environment and feels nothing but empathy for students who are being forced to decide if they will stay close to their in-state support system or seek education out of state.

It's just a matter of what you prioritize, and it's OK to prioritize being in your home state or city with your family with the intention of building those skills in other ways, Belmonte said. I hope those opportunities will continue to grow as we settle from all the changes that have been happening very rapidly.

Medical Students for Choice pamphlet on August 24.

In the aftermath of Roe v. Wade being overturned, the intersection of policy and medicine is becoming increasingly clear to the general public. Abortion has become a top issue in the upcoming midterm elections and is pushing more people to vote in November.

But for medical students and providers in Oklahoma, the overturning of Roe v. Wade was more so a continuation of medicine clashing with policy.

Regens, who is also a member of the American College of Obstetricians and Gynecologists, said she tries to use her experience in advocacy work to equip medical students and residents. She organizes an advocacy curriculum for OB-GYN residents and provides sessions in the colleges reproductive course reflecting on Oklahomas status in womens health.

She also invites students in OUs OB-GYN interest group to advocacy days at the Oklahoma state Capitol, where they have advocated against several bills restricting abortion that have come through the state over the years.

The main issue these students face is that many legislators have made up their minds on abortion, Regens said. ACOG is against any bill that limits access to abortion care, but Oklahoma providers must also move the needle on issues like maternal mortality and access to contraception.

Regens said they have to pick and choose their battles.

Its frustrating to medical students like Jarshaw. She has always seen the gaps in Oklahomas reproductive health care system and is dedicating her 20s to clinical training so she can help fill them.

When Roe v. Wade was overturned, Jarshaw woke up to five texts from friends confirming what she already knew was coming. Her education would continue to be dictated by government officials who hadnt completed the years of medical training she had.

All she could do was put her phone down, get up and clean something in her apartment. She took care of what was around because she knew as many medical students did that day she couldnt fix what was happening outside her closed doors.

Read the original post:
OU medical students fear state legislation will further restrict access to comprehensive reproductive education - The Oklahoma Daily